WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Â Proceeds will be used...
922 Views
Quick Note - Almost at the Finishing Line
Latest Update:Glass Lewis and ISS have advised Wuxi's shareholders to approve the offer from the consortium. We believe Shareholders will vote in...
545 Views
WuXi PharmaTech: How to Argue for a Few Dollars More
WuXi PharmaTech's recent placements of stock of its NEEQ-listed Syn-The-All Pharmaceutical Co. subsidiary have been at a substantially higher...
514 Views
WuXi's Chairman and Ally Bridge Offer $46/ADS in Going Private Bid
WuXi's Founder, Chairman and CEO, Dr. Ge Li and private equity firm Ally Bridge have made a non-binding offer to take the company private for...
658 Views
Increasing Opportunities in Emerging Market CROs
Life sciences R&D spending growth in Asia is outpacing the developed world (US, Canada, and Europe). An article from the January 2, 2014,...
386 Views